Treatment of primary sclerosing cholangitis

Floreani, Annarosa; Martin, Sara De

doi:10.1016/j.dld.2021.04.028

Cited by 23 publications

(24 citation statements)

References 73 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…BEZA (400 mg/day) led to this achievement in 45% of patients (41% PSC, 55% PBC), whereas only 11% reached the primary endpoint in the placebo group ( p = 0.003). This effect in relieving cholestasis-associated pruritus occurs via an autotaxin-independent mechanism [ 46 ]. This improving effect on pruritus ensures that fibrates should be employed as a second-line option for PBC therapy in patients experiencing moderate to severe pruritus.…”

Section: Other Therapeutic Agents For Pbcmentioning

confidence: 99%

Update on the Pharmacological Treatment of Primary Biliary Cholangitis

2022

Self Cite

View full text Add to dashboard Cite

Ursodeoxycholic acid (UDCA) is the first-line therapy used for the treatment of PBC. In recent years, new pharmacological agents have been proposed for PBC therapy to cure UDCA-non-responders. Obeticholic acid (OCA) is registered in many countries for PBC, and fibrates also seem to be effective in ameliorating biochemistry alteration and symptoms typical of PBC. Moreover, a variety of new agents, acting with different mechanisms of action, are under clinical evaluation for PBC treatment, including PPAR agonists, anti-NOX agents, immunomodulators, and mesenchymal stem cell transplantation. Since an insufficient amount of data is currently available about the effect of these novel approaches on robust clinical endpoints, such as transplant-free survival, their clinical approval needs to be supported by the consistent improvement of these parameters. The intensive research in this field will hopefully lead to a novel treatment landscape for PBC in the near future, with innovative therapies based on the combination of multiple agents acting on different pathogenetic mechanisms.

show abstract

Section: Other Therapeutic Agents For Pbcmentioning

confidence: 99%

Update on the Pharmacological Treatment of Primary Biliary Cholangitis

2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…Badania wykazują, że stosowanie UDCA modyfikuje stężenia wskaźników cholestazy w surowicy, jednak nie stwierdzono jego wpływu na czas przeżycia chorych. Mimo to jest często stosowanym lekiem w PSC [21].…”

Section: Dyskusjaunclassified

“…Reasumując, przyczyniają się do łagodzenia objawów przewlekłej choroby wątroby. Udowodniono, że stosowanie statyn u chorych PSC, zmniejsza ryzyko zgonu i przeszczepu wątroby [21].…”

Section: Dyskusjaunclassified

Primary sclerosing cholangitis - an insidious enemy of the liver - case report

Knop

Piasecka

Kochanowska

et al. 2022

J Educ Health Sport

View full text Add to dashboard Cite

show abstract

“…The PXR activator rifampicin is used for the treatment of itches in cholestatic patients, and also for symptomatic gallstone disease [ 39 , 54 ]. Studies on rifampicin-treated patients undergoing cholecystectomy suggested that the therapeutic effect of the drug is due to the upregulation of the phase II uridine diphosphate glucuronosyltransferase (UGT1A1) and the multidrug resistance protein 2 transporter (MRP2), both mediated by PXR activation [ 41 , 55 , 56 ].…”

Section: Pxr and Cholestasismentioning

confidence: 99%

The Nuclear Receptor PXR in Chronic Liver Disease

Sayaf

Zanotto

Russo

et al. 2021

Cells

Self Cite

View full text Add to dashboard Cite

Pregnane X receptor (PXR), a nuclear receptor known for modulating the transcription of drug metabolizing enzymes and transporters (DMETs), such as cytochrome P450 3A4 and P-glycoprotein, is functionally involved in chronic liver diseases of different etiologies. Furthermore, PXR activity relates to that of other NRs, such as constitutive androstane receptor (CAR), through a crosstalk that in turn orchestrates a complex network of responses. Thus, besides regulating DMETs, PXR signaling is involved in both liver damage progression and repair and in the neoplastic transition to hepatocellular carcinoma. We here summarize the present knowledge about PXR expression and function in chronic liver diseases characterized by different etiologies and clinical outcome, focusing on the molecular pathways involved in PXR activity. Although many molecular details of these finely tuned networks still need to be fully understood, we conclude that PXR and its modulation could represent a promising pharmacological target for the identification of novel therapeutical approaches to chronic liver diseases.

show abstract

Treatment of primary sclerosing cholangitis

Cited by 23 publications

References 73 publications

Update on the Pharmacological Treatment of Primary Biliary Cholangitis

Update on the Pharmacological Treatment of Primary Biliary Cholangitis

Primary sclerosing cholangitis - an insidious enemy of the liver - case report

The Nuclear Receptor PXR in Chronic Liver Disease

Contact Info

Product

Resources

About